| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 32 | 2025 | 2483 | 1.930 |
Why?
|
| Receptor, ErbB-2 | 16 | 2025 | 496 | 1.410 |
Why?
|
| Physical and Rehabilitation Medicine | 2 | 2022 | 33 | 0.910 |
Why?
|
| Lymphedema | 2 | 2023 | 19 | 0.860 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 481 | 0.780 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 4 | 0.650 |
Why?
|
| Phyllodes Tumor | 2 | 2013 | 11 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 714 | 0.540 |
Why?
|
| Quinazolines | 11 | 2023 | 175 | 0.530 |
Why?
|
| Trastuzumab | 11 | 2025 | 139 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1250 | 0.530 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 321 | 0.510 |
Why?
|
| Receptors, Estrogen | 11 | 2022 | 789 | 0.450 |
Why?
|
| Neoplasms | 5 | 2023 | 2751 | 0.450 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 28 | 0.440 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 24 | 0.440 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 1431 | 0.430 |
Why?
|
| Osteosarcoma | 1 | 2013 | 259 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 7 | 2025 | 353 | 0.360 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2016 | 254 | 0.350 |
Why?
|
| Ki-67 Antigen | 3 | 2022 | 115 | 0.330 |
Why?
|
| Tamoxifen | 5 | 2016 | 363 | 0.330 |
Why?
|
| Immunohistochemistry | 4 | 2022 | 1717 | 0.270 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 269 | 0.230 |
Why?
|
| STAT5 Transcription Factor | 2 | 2022 | 89 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 880 | 0.220 |
Why?
|
| Female | 37 | 2025 | 65361 | 0.220 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 1682 | 0.220 |
Why?
|
| Humans | 42 | 2025 | 122971 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 501 | 0.200 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 126 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.200 |
Why?
|
| Human Trafficking | 1 | 2022 | 41 | 0.200 |
Why?
|
| Quinolines | 1 | 2022 | 97 | 0.190 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 3299 | 0.190 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 37 | 0.190 |
Why?
|
| Gene Editing | 1 | 2023 | 186 | 0.180 |
Why?
|
| Physical Therapy Modalities | 1 | 2021 | 50 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 1021 | 0.170 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 23 | 0.170 |
Why?
|
| Gene Expression | 3 | 2020 | 1592 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 106 | 0.160 |
Why?
|
| Signal Transduction | 9 | 2025 | 4524 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 66 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Middle Aged | 13 | 2020 | 25885 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 404 | 0.150 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 134 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 98 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 49 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1885 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 538 | 0.130 |
Why?
|
| Estradiol | 2 | 2016 | 534 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2023 | 12083 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 107 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 471 | 0.130 |
Why?
|
| Adult | 14 | 2022 | 28944 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2016 | 209 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 225 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2018 | 697 | 0.120 |
Why?
|
| Mice | 13 | 2023 | 17647 | 0.120 |
Why?
|
| Quality of Life | 2 | 2024 | 1921 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1881 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 70 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 108 | 0.110 |
Why?
|
| Granulomatous Mastitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hospitals, County | 1 | 2013 | 23 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 62 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 4308 | 0.110 |
Why?
|
| Transcriptome | 2 | 2016 | 909 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 97 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 449 | 0.110 |
Why?
|
| Animals | 15 | 2023 | 33923 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 520 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 220 | 0.100 |
Why?
|
| Fibroadenoma | 1 | 2012 | 9 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2011 | 285 | 0.100 |
Why?
|
| Oncogenes | 2 | 2013 | 172 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 632 | 0.100 |
Why?
|
| Atrioventricular Node | 1 | 2011 | 16 | 0.100 |
Why?
|
| Death, Sudden | 1 | 2011 | 45 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 65 | 0.090 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 103 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 654 | 0.090 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2009 | 78 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 882 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 4688 | 0.080 |
Why?
|
| Models, Biological | 1 | 2014 | 1440 | 0.080 |
Why?
|
| Prognosis | 4 | 2020 | 4503 | 0.080 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 92 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1222 | 0.080 |
Why?
|
| Lentivirus | 1 | 2008 | 84 | 0.080 |
Why?
|
| Smad5 Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Smad1 Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Exercise | 2 | 2024 | 800 | 0.070 |
Why?
|
| Breast | 2 | 2022 | 214 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2009 | 679 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2006 | 12 | 0.070 |
Why?
|
| Adnexa Uteri | 1 | 2006 | 9 | 0.070 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 14 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 18998 | 0.070 |
Why?
|
| Ovarian Diseases | 1 | 2006 | 28 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 63 | 0.070 |
Why?
|
| Fistula | 1 | 2006 | 50 | 0.070 |
Why?
|
| Antibodies, Blocking | 1 | 2006 | 61 | 0.070 |
Why?
|
| Testis | 1 | 2007 | 407 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2016 | 222 | 0.060 |
Why?
|
| Mutation | 5 | 2018 | 5794 | 0.060 |
Why?
|
| Ovary | 1 | 2007 | 390 | 0.060 |
Why?
|
| Biopsy | 2 | 2022 | 1256 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 1473 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2008 | 973 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 817 | 0.060 |
Why?
|
| Pelvic Neoplasms | 1 | 2003 | 21 | 0.060 |
Why?
|
| Mammary Glands, Animal | 2 | 2022 | 482 | 0.060 |
Why?
|
| Recombinational DNA Repair | 1 | 2023 | 19 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 78 | 0.050 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 865 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6343 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 80 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2824 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 147 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 346 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 366 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 250 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 399 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 71 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 67 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 576 | 0.040 |
Why?
|
| Cell Division | 2 | 2013 | 793 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2321 | 0.040 |
Why?
|
| Melanoma | 1 | 2006 | 837 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 805 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1354 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 300 | 0.040 |
Why?
|
| Male | 4 | 2019 | 59957 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 907 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 1164 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 133 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 606 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 240 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1680 | 0.030 |
Why?
|
| Apoptosis | 2 | 2013 | 1792 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 174 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 1862 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 664 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 183 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1617 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 117 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 207 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 351 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 3782 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 286 | 0.030 |
Why?
|
| Mammography | 1 | 2013 | 113 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 342 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6216 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 145 | 0.030 |
Why?
|
| Steroids | 1 | 2013 | 203 | 0.030 |
Why?
|
| Triazoles | 1 | 2013 | 138 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 29 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 3075 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 572 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 428 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 492 | 0.020 |
Why?
|
| Forensic Pathology | 1 | 2011 | 7 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1586 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 731 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 335 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 212 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 239 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5025 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 874 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 372 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 51 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 351 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1419 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 606 | 0.020 |
Why?
|
| Keratin-9 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Alpharetrovirus | 1 | 2008 | 5 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 181 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 92 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 946 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 252 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2008 | 108 | 0.020 |
Why?
|
| Smad8 Protein | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sertoli Cell Tumor | 1 | 2007 | 8 | 0.020 |
Why?
|
| Granulosa Cell Tumor | 1 | 2007 | 40 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 868 | 0.020 |
Why?
|
| HIV | 1 | 2008 | 179 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2029 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1006 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 122 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 255 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2104 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 139 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2006 | 50 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 88 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 983 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 182 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1301 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 2952 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 72 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8830 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 811 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2006 | 236 | 0.020 |
Why?
|
| Fertility | 1 | 2007 | 263 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2006 | 172 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2006 | 197 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 15934 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 1999 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 507 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 654 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2007 | 799 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 422 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 181 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4222 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2443 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2003 | 296 | 0.010 |
Why?
|
| Child | 1 | 2022 | 24170 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1119 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2396 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 428 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7126 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3319 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2048 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 1679 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 1389 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 9950 | 0.010 |
Why?
|